Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study
Open Access
- 1 October 2016
- journal article
- research article
- Published by Taylor & Francis in HIV/AIDS - Research and Palliative Care
- Vol. ume 8, 165-174
Abstract
Dyslipidemia, hypertension, inflammation, and coronary heart disease (CHD) are adverse events in human immunodeficiency virus (HIV)-infected patients even if they are receiving antiretroviral therapy (ART). Yet, data on CHD risk induced by HIV or ART in sub-Saharan Africa are limited. The aim of this longitudinal study was to describe changes in CHD risk profiles measured by lipids, inflammatory markers, and Framingham scores among HIV-positive patients previously reported from Harare, Zimbabwe. Patients were grouped into ART-experienced patients (n=147) and ART-naïve patients (n=23) and followed up for 9 months. Generalized least squares random-effects modeling was applied to explain changes in total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein, TC/HDL ratio, myeloperoxidase, highly sensitive C-reactive protein, and Framingham scores over the 9-month period. Independent variables included age, sex, monthly earning, body mass index, systolic blood pressure (SBP), diastolic blood pressure, duration of HIV diagnosis, duration of ART, viral load, and CD4 count. In ART-experienced patients, there was a substantial decrease in TC over time, ART-negative patients showed a significant increase in TC and HDL over time, and the increase in TC was associated with high viral load and low duration of HIV diagnosis, while increase in HDL was associated with young age, low body mass index, and low SBP. Framingham risk scores increased with time in ART-positive patients, and the change was positively correlated with age, sex, high SBP, and low HDL. There was no association between calculated CHD risk (TC/HDL ratio or Framingham score) and changes in levels of inflammatory markers (myeloperoxidase and highly sensitive C-reactive protein) in any of the patient groups. In conclusion, ART-experienced HIV-positive patients show changes in lipid values over time that makes it necessary to include lipid monitoring in order to reduce any risk of long-term CHD.Keywords
This publication has 51 references indexed in Scilit:
- Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional surveyBMC Public Health, 2013
- Lipid Profile of Anti-Retroviral Treatment-Naοve HIV-Infected Patients in Jos, NigeriaAnnals of Medical and Health Sciences Research, 2013
- Dyslipidemia in an HIV-Positive Antiretroviral Treatment-Naive Population in Dar es Salaam, TanzaniaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Dyslipidemia and lipid management in HIV-infected patientsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2011
- Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income CountriesCurrent Problems in Cardiology, 2010
- Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan womenAIDS Research and Therapy, 2010
- Inflammation, Hemostasis, and the Risk of Kidney Function Decline in the Atherosclerosis Risk in Communities (ARIC) StudyAmerican Journal of Kidney Diseases, 2009
- Lipid Management in Patients Who Have HIV and Are Receiving HIV TherapyEndocrinology and Metabolism Clinics of North America, 2009
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLOS Medicine, 2004
- HIV infection, HAART, and endothelial adhesion molecules: current perspectivesThe Lancet Infectious Diseases, 2004